Building Better Degraders: Targeted Protein Degradation Partners From Lead Discovery To Production

Targeted Protein Degradation (TPD) has transformed the approach to addressing "undruggable" targets in drug development. This innovative therapeutic modality offers a promising opportunity to target proteins that have traditionally been considered challenging or "undruggable" by conventional small molecule inhibitors. However, as a novel modality, TPD introduces unique hurdles across various stages of drug development, including lead discovery, Active Pharmaceutical Ingredient (API) development, and manufacturing.

Learn from MilliporeSigma's experts as they provide insights into the latest advances in chemical building blocks for protein degradation, encompassing warheads, linkers, and ligands, and their role in constructing superior degraders. Additionally, discover the significance of choosing the right Contract Development and Manufacturing Organization (CDMO) to provide support throughout the development and manufacturing process once the candidate degrader has been identified.